Could a bile acid blocker ease CF constipation?

NCT ID NCT06413368

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether Maralixibat, a drug that increases bile acids in the colon, can improve stool consistency in 20 children with cystic fibrosis who have chronic constipation. Participants will take the drug for two weeks alongside their usual laxatives. The goal is to see if it helps soften stools and makes bowel movements easier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Maralixibat (Livmarli)

What this could lead to

If it works, this could point toward a new treatment option for constipation in children with cystic fibrosis.

What could go wrong

This is a very small, early pilot study with only 20 participants and a short 2-week treatment period. Results may not apply to all patients, and the drug may not work better than standard laxatives.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

constipation disorder cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital Los Angeles

    RECRUITING

    Los Angeles, California, 90027, United States

    Contact Email: •••••@•••••

    Contact